- STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trialsNew GSK CEO Luke Miels outlined his strategy to help the company navigate a patent cliff and get on a path toward long-term growth.STAT · 26m ago↗ source
- STAT+: FDA staff reiterate concerns about Replimune skin cancer treatmentRegulators at the FDA have reiterated concerns that Replimmune does not have adequate data to support an approval of its investigational skin cancer treatment.STAT · 57m ago↗ source
- STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and moreThe FDA said a Capricor stem cell treatment for Duchenne muscular dystrophy did not meet a Phase 3 trial's objectives — contrary to company claimsSTAT